Five Prime Therapeutics Inc. (NASDAQ:FPRX)’s share price dropped 3.7% during mid-day trading on Wednesday . The stock traded as low as $44.00 and last traded at $44.56, with a volume of 163,099 shares. The stock had previously closed at $46.25.

FPRX has been the subject of several recent research reports. Jefferies Group set a $60.00 price target on Five Prime Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 5th. Leerink Swann reissued a “buy” rating and set a $45.00 price target on shares of Five Prime Therapeutics in a research report on Friday, July 15th. Credit Suisse Group AG reissued a “buy” rating on shares of Five Prime Therapeutics in a research report on Tuesday, July 12th. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $48.00 price target on shares of Five Prime Therapeutics in a research report on Thursday, May 19th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $52.33.

The company’s 50 day moving average price is $47.17 and its 200 day moving average price is $42.40. The firm has a market capitalization of $1.20 billion and a price-to-earnings ratio of 5.00.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. The company earned $9.23 million during the quarter, compared to the consensus estimate of $6.38 million. Five Prime Therapeutics’s revenue for the quarter was up 46.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.45) EPS. On average, analysts expect that Five Prime Therapeutics Inc. will post ($2.37) EPS for the current year.

In related news, Director Peder Jensen sold 12,195 shares of the stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total value of $603,652.50. Following the completion of the transaction, the director now owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director William R. Ringo sold 500 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $50.77, for a total transaction of $25,385.00. Following the completion of the transaction, the director now directly owns 500 shares of the company’s stock, valued at approximately $25,385. The disclosure for this sale can be found here.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.